Hamza Naciri Bennani, Augustin Twite Banza, Diane Giovannini, Lionel Motte, Johan Noble, Alexandra Corbu, Paolo Malvezzi, Thomas Jouve, Lionel Rostaing
Membranous nephropathy constitutes approximately 20% of adult nephrotic syndrome cases. In approximately 80% of cases, membranous nephropathy is primary, mediated by IgG autoantibodies primarily targeting podocyte antigens (PLA2R, THSD7A, etc.). The treatment involves a combination of corticosteroids and cyclophosphamide or anti-CD20-based therapies, e.g., rituximab. In the event of significant proteinuria and in order to avoid the urinary elimination of rituximab, therapeutic apheresis, in particular semi-specific immunoadsorption, may be an option allowing for a reduction in proteinuria and autoantibodies before initiating treatment with rituximab...
February 26, 2024: Journal of Personalized Medicine